Tysabri

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Progressive Multifocal Leukoencephalopathy

Conditions

Progressive Multifocal Leukoencephalopathy

Trial Timeline

Jun 1, 2017 → Dec 31, 2023

NCT ID

NCT03399981

About Tysabri

Tysabri is a pre-clinical stage product being developed by Biogen for Progressive Multifocal Leukoencephalopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT03399981. Target conditions include Progressive Multifocal Leukoencephalopathy.

What happened to similar drugs?

2 of 20 similar drugs in Progressive Multifocal Leukoencephalopathy were approved

Approved (2) Terminated (4) Active (14)

🔄Enzalutamide + PlaceboAstellas PharmaPhase 3

🔄HRS-4357 injection + Enzalutamide；AbirateroneJiangsu Hengrui MedicinePhase 3

🔄Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3

❌FTY720 + PlaceboNovartisPhase 3

✅BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved

🔄BAF312 + PlaceboNovartisPhase 3

✅Imatinib mesylateNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03399981	Pre-clinical	Completed	Jun 1, 2017	Dec 31, 2023	Progressive Multifocal Leukoencephalopathy
NCT01071512	Pre-clinical	Completed	Apr 1, 2010	Jan 1, 2016	Multiple Sclerosis
NCT00937677	Pre-clinical	Completed	Nov 1, 2007	Nov 1, 2010	Multiple Sclerosis
NCT00493298	Pre-clinical	Completed	Jun 29, 2007	Nov 1, 2023	Relapsing-Remitting Multiple Sclerosis

Competing Products

20 competing products in Progressive Multifocal Leukoencephalopathy

See all competitors

Product	Company	Stage	Hype Score
AP01	Avalyn Pharmaceuticals	Phase 2	32
Enzalutamide + Placebo	Astellas Pharma	Phase 3	40
Enzalutamide	Astellas Pharma	Phase 2	35
dirucotide + Placebo	Eli Lilly	Phase 2/3	38
dirucotide	Eli Lilly	Phase 2/3	30
HRS-4357 injection + Enzalutamide；Abiraterone	Jiangsu Hengrui Medicine	Phase 3	47
ABBV-8E12 + Placebo solution for IV infusion on Day 15	AbbVie	Phase 2	27
Placebo + ABBV-8E12	AbbVie	Phase 2	27
ABBV-8E12	AbbVie	Phase 1	29
AZD4635 + Durvalumab + Cabazitaxel	AstraZeneca	Phase 2	35
antisense oligonucleotide + placebo	Novartis	Phase 1	29
Trametinib 2 mg	Novartis	Pre-clinical	26
Everolimus	Novartis	Phase 2	35
sunitinib + everolimus + chemotherapies recommended in france	Novartis	Pre-clinical	26
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)	Novartis	Phase 3	47
FTY720 + Placebo	Novartis	Phase 3	32
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273	Novartis	Approved	43
Mayzent	Novartis	Pre-clinical	26
BAF312 + Placebo	Novartis	Phase 3	40
Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC)	Novartis	Phase 1/2	39